Prognostic value of geriatric screening and assessment for overall survival in older patients with cancer

2014 ◽  
Vol 5 ◽  
pp. S22
Author(s):  
c. Kenis ◽  
P. Heeren ◽  
L. Decoster ◽  
K. Van Puyvelde ◽  
J. De Grève ◽  
...  
Keyword(s):  
Overall Survival ◽  
Older Patients ◽  
Prognostic Value ◽  
Patients With Cancer ◽  
Geriatric Screening

Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 11551-11551
Author(s):  
Elena Paillaud ◽  
Pierre Soubeyran ◽  
Nadia Oubaya ◽  
Etienne Brain ◽  
Marianne Fonck ◽  
...  
Keyword(s):  
Overall Survival ◽  
Older Patients ◽  
Prognostic Value ◽  
Prognostic Score ◽  
Performance Status ◽  
Glasgow Prognostic Score ◽  
Pooled Analysis ◽  
Clinical Model ◽  
Patients With Cancer ◽  
Net Reclassification Improvement

11551 Background: To assess prognostic value of routine biomarkers in older patients with cancer. Methods: A pooled analysis of three prospective multicentre cohorts, ELCAPA, PHRC Aquitaine and ONCODAGE was conducted. Patients aged 70 years or older, with cancer were included. Biomarkers collected were plasmatic C-reactive protein, albumin and a combined score: Glasgow Prognostic Score (GPS). The GPS comprised three categories (0: CRP≤10 mg/L, albumin≥35 g/L; 1: CRP≤10 mg/L and albumin < 35 g/L, or CRP > 10 mg/L and albumin≥35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L).The primary endpoint was overall survival at 12 months. Multivariable Cox models were used, adjusting for age, sex, localisation, metastatic status, performance status, frailty screening index, the G8. Discriminative properties were assessed using Harrell C index and NRI (Net Reclassification Improvement). Results: Overall 1800 patients were analyzed (ELCAPA: N = 543, PHRC Aquitaine: N = 253, ONCODAGE: N = 1004; mean age: 78.5±5.5 years; 61.7% of men; 37% metastatic; most frequent localisations: breast (34.9%) and colon-rectum (17.7%); 70.7% of patients screened at risk of frailty with G8). Overall survival was 71.1%. GPS was independently associated with death (among normal G8: GPS 1: Hazard Ratio (HR) = 4.48; 95% Confidence Interval (95% CI) = [2.03; 9.89], GPS 2: 11.64 [4.54; 29.81], among abnormal G8: GPS 1: 2.45 [1.79; 3.34], GPS 2: 3.97 [2.93; 5.37]. The addition of GPS to the clinical model (Harell C: 0.82 [0.80; 0.83]) improved discrimination (Harell C: 0.84 [0.82; 0.85], NRI: 11% [5; 19]). Conclusions: GPS could be used in older patients with cancer to help decision-making and prognosis assessment.

Performance of Two Geriatric Screening Tools in Older Patients With Cancer

2014 ◽  
Vol 32 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Cindy Kenis ◽  
Lore Decoster ◽  
Katrien Van Puyvelde ◽  
Jacques De Grève ◽  
Godelieve Conings ◽  
...  
Keyword(s):  
Activities Of Daily Living ◽  
Daily Living ◽  
Older Patients ◽  
Prognostic Value ◽  
Functional Decline ◽  
Treatment Decision ◽  
Risk Profile ◽  
Screening Tools ◽  
Patients With Cancer ◽  
Geriatric Screening

Purpose To compare the diagnostic characteristics of two geriatric screening tools (G8 and Flemish version of the Triage Risk Screening Tool [fTRST]) to identify patients with a geriatric risk profile and to evaluate their prognostic value for functional decline and overall survival (OS). Patients and Methods Patients ≥ 70 years old with a malignant tumor were included if a new cancer event occurred requiring treatment decision. Geriatric screening with G8 and fTRST (cutoff ≥ 1 [fTRST (1)] and ≥ 2 [fTRST (2)] evaluated) was performed in all patients, as well as a geriatric assessment (GA) evaluating social situation, functionality (activities of daily living [ADL] + instrumental activities of daily living [IADL]), cognition, depression, and nutrition. Functionality was re-evaluated 2 to 3 months after cancer treatment decision, and death rate was followed. Functional decline and OS were evaluated in relation to normal versus abnormal score on both screening tools. Results Nine hundred thirty-seven patients were included (October 2009 to July 2011). G8 and fTRST (1) showed high sensitivity (86.5% to 91.3%) and moderate negative predictive value (61.3% to 63.4%) to detect patients with a geriatric risk profile. G8 and fTRST (1) were strongly prognostic for functional decline on ADL and IADL, and G8, fTRST (1), and fTRST (2) were prognostic for OS (all P < .001). G8 had the strongest prognostic value for OS (hazard ratio for G8 normal v abnormal, 0.38; 95% CI, 0.27 to 0.52). Conclusion Both geriatric screening tools, G8 and fTRST, are simple and useful instruments in older patients with cancer for identifying patients with a geriatric risk profile and have a strong prognostic value for functional decline and OS.

scholarly journals The added value of geriatric screening and assessment for predicting overall survival in older patients with cancer

Cancer ◽  
2018 ◽  
Vol 124 (18) ◽  
pp. 3753-3763 ◽  
Author(s):  
Cindy Kenis ◽  
Abdelbari Baitar ◽  
Lore Decoster ◽  
Jacques De Grève ◽  
Jean-Pierre Lobelle ◽  
...  
Keyword(s):  
Overall Survival ◽  
Older Patients ◽  
Added Value ◽  
Patients With Cancer ◽  
Geriatric Screening

scholarly journals The prognostic value of 3 commonly measured blood parameters and geriatric assessment to predict overall survival in addition to clinical information in older patients with cancer

Cancer ◽  
2018 ◽  
Vol 124 (18) ◽  
pp. 3764-3775 ◽  
Author(s):  
Abdelbari Baitar ◽  
Cindy Kenis ◽  
Lore Decoster ◽  
Jacques De Grève ◽  
Jean-Pierre Lobelle ◽  
...  
Keyword(s):  
Overall Survival ◽  
Geriatric Assessment ◽  
Older Patients ◽  
Prognostic Value ◽  
Clinical Information ◽  
Blood Parameters ◽  
Patients With Cancer

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer

2017 ◽  
Vol 83 ◽  
pp. 211-219 ◽  
Author(s):  
Claudia Martinez-Tapia ◽  
Elena Paillaud ◽  
Evelyne Liuu ◽  
Christophe Tournigand ◽  
Rima Ibrahim ◽  
...  
Keyword(s):  
Older Patients ◽  
Prognostic Value ◽  
Health Problems ◽  
Screening Tools ◽  
Patients With Cancer ◽  
Multidimensional Health

Overall survival in older patients with cancer

2018 ◽  
Vol 10 (1) ◽  
pp. 25-35 ◽  
Author(s):  
Beatrice J Edwards ◽  
Xiaotao Zhang ◽  
Ming Sun ◽  
Juhee Song ◽  
Peter Khalil ◽  
...  
Keyword(s):  
Older Adults ◽  
Overall Survival ◽  
Older Patients ◽  
Eastern Cooperative Oncology Group ◽  
Karnofsky Performance Scale ◽  
Haematological Malignancies ◽  
Patients With Cancer ◽  
Number Of Patients ◽  
Traditional Performance

ObjectivesA growing number of patients with cancer are older adults. We sought to identify the predictors for overall survival (OS) in older adults with solid tumour and haematological malignancies between January 2013 and December 2016.MethodsRetrospective cohort study. A comprehensive geriatric assessment was performed, with a median follow-up of 12.8 months. Analysis: univariate and multivariate Cox proportional hazards regression analysis.ResultsIn this study, among the 455 patients with last follow-up date or date of death, 152 (33.4%) died during the follow-up. The median follow-up is 12.8 months (range 0.2–51.1 months) and the median OS is 20.5 months (range 0.3–44.5 months). Among all older patients with cancer, predictors of OS included male gender, cancer stage, malnutrition, history of smoking, heavy alcohol use, frailty, weight loss, major depression, low body weight and nursing home residence. Traditional performance scores (Eastern Cooperative Oncology Group (ECOG) and Karnofsky Performance Scale (KPS)) were predictors of OS. Independent predictors included age >85 years and haematological malignancies. Among solid tumours (n=311) in addition to the above predictors, comorbidity, gait speed and vitamin D deficiency were associated with OS.ConclusionsWe identified specific geriatric factors associated with OS in older patients with cancer, and comparable in predictive ability to traditional performance scores such as KPS and ECOG. Prospective studies will be necessary to confirm our findings.

Malnutrition and overall survival in older patients with cancer

2020 ◽  
Author(s):  
Xiaotao Zhang ◽  
Linda Pang ◽  
Shreela V. Sharma ◽  
Ruosha Li ◽  
Alan G. Nyitray ◽  
...  
Keyword(s):  
Overall Survival ◽  
Older Patients ◽  
Patients With Cancer

scholarly journals The prognostic value of Immunoscore in patients with cancer: A pooled analysis of 10,328 patients

2020 ◽  
Vol 35 (3) ◽  
pp. 3-13 ◽  
Author(s):  
Xingxia Zhang ◽  
Jie Yang ◽  
Liang Du ◽  
Yong Zhou ◽  
Ka Li
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Prognostic Value ◽  
Disease Free Survival ◽  
Pooled Analysis ◽  
Disease Specific Survival ◽  
Free Survival ◽  
Patients With Cancer ◽  
Disease Free ◽  
Disease Specific

Objectives: Over the past decade, some publications have reported that Immunoscore was associated with the prognosis of several cancers. To better understand this issue, we conducted this pooled analysis. Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from their inceptions to 15 May 2019 to identify relevant articles. The pooled hazard ratio (HR) and 95% confidence interval (CI) was estimated for overall survival, disease-free survival, and disease-specific survival. Results: A total of 26 cohort studies with 10,328 patients involving eight cancer specialties were evaluated mainly by the consensus Immunoscore. The pooled analysis indicated that a lower Immunoscore was associated with a poor overall survival (HR 2.23, 95% CI 1.58, 2.70), disease-free survival (HR 2.40, 95% CI 1.96, 2.49), and disease-specific survival (HR 2.81, 95% CI 2.10, 3.77) for all cancers. The same convincing results were found in colorectal cancer, gastric cancer, and non-small cell lung cancer (especially the consensus Immunoscore for colon cancer). In five other types of cancer the results were similar, but the sample sizes were limited. Conclusions: These findings support that Immunoscore is significantly associated with the prognosis of patients with cancer. It provides a reliable estimate of the risk of recurrence in patients with colon cancer. However, more high-quality studies are necessary to assess the prognostic value of Immunoscore in non-colon cancers.

KLRK1 as a Prognostic Biomarker for Lung Adenocarcinoma Cancer

2021 ◽  
Author(s):  
Yanan Zhang ◽  
Zeyang Chen ◽  
Guanqi Gao
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Lung Adenocarcinoma ◽  
Older Patients ◽  
Prognostic Value ◽  
Prognostic Biomarker ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Lung Adenocarcinoma Cancer

Abstract Background. Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year. Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor. However, there has not been one research of KLRK1 as a biomarker in lung cancer.Methods. Data including patients` clinical characteristics and RNAseq information of KLRK1 from TCGA were downloaded. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male. Evaluations of mRNA expression, diagnostic value by ROC (Receiver operating characteristic) curves and prognostic value by survival curve, Cox model and subgroup analysis were performed. The CCK-8 assay investigated the proliferation rate and the wound healing assay assessed the migratory ability in vitro.Results. The expression of KLRK1 in tumor was lower than that in normal tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Patients with high KLRK1 expression presented an improved overall survival (P=0.0036) and relapse free survival (P=0.0031). KLRK1 was found to have significant prognostic value in lung adenocarcinoma (P=0.015), stage I/II (P=0.03), older patients (P=0.0052), and male (P=0.0047) by subgroup overall survival analysis, and in lung adenocarcinoma (P=0.0094), stage I/II (P=0.0076), older patients (P=0.0072) , and male (P=0.0033) by subgroup relapse free survival analysis. Lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival (P=0.015) and relapse free survival (P=0.0094). In vitro studies indicated that KLRK1 inhibited tumor cell proliferation and migration.Conclusions. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a prognostic biomarker for lung adenocarcinoma cancer.

Sign in / Sign up

Export Citation Format

Share Document